Gene therapy strategies in neurodegenerative diseases.
Treatment of neurodegenerative diseases by classical pharmacotherapy is restricted by blood-brain barrier which prevents access to the brain of potentially therapeutic molecules. Recent progress in the knowledge of pathophysiological molecular processes, and in the development of molecular biotechnology have opened the way to new therapeutic interventions for these disorders. This chapter reviews the most recent gene therapy strategies using experimental models for neurodegenerative diseases.
Giménez y Ribotta
M
M
INSERM U.336, Development, Plasticity and Aging of the Nervous System, University of Montpellier II, France. mgyr@univ-montp2.fr
D000544:Alzheimer Disease / Q000628:therapy; D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy; D000818:Animals; D003638:Deafness / Q000628:therapy; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D006816:Huntington Disease / Q000628:therapy; D019636:Neurodegenerative Diseases / Q000628:therapy*; D009474:Neurons; D010300:Parkinson Disease / Q000628:therapy; D020734:Parkinsonian Disorders / Q000628:therapy; D011401:Promoter Regions, Genetic; D012174:Retinitis Pigmentosa / Q000628:therapy